Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Ramps Up Cancer Portfolio With $1.7bn Ignyta Buy

Executive Summary

The Swiss giant's acquisition of Ignyta to get hold of the latter's closely-watched NSCLC drug entrectinib will potentially trigger an intriguing fight for market share in the near future with Loxo Oncology and Bayer's larotrectinib.

Advertisement

Related Content

Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm
Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data
Roche Pushes Personalization With $2.4Bn Foundation Buy-Out
Roche Pushes Personalization With $2.4bn Foundation Buy-Out
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
M&A Analysis: February, Onco And Cardio Deals Invade Frosty Month
Biopharma Quarterly Deal-making Statistics, Q4 2017
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
New Drugs Shine But Biosimilars Blunt Roche Revenue Rise
Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel